Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Operating Income (2016 - 2025)

CorMedix's Operating Income history spans 14 years, with the latest figure at $59.1 million for Q4 2025.

  • For Q4 2025, Operating Income rose 357.05% year-over-year to $59.1 million; the TTM value through Dec 2025 reached $150.1 million, up 771.59%, while the annual FY2025 figure was $150.1 million, 771.59% up from the prior year.
  • Operating Income for Q4 2025 was $59.1 million at CorMedix, up from $51.3 million in the prior quarter.
  • Across five years, Operating Income topped out at $59.1 million in Q4 2025 and bottomed at -$16.7 million in Q1 2024.
  • The 5-year median for Operating Income is -$7.2 million (2021), against an average of $1.8 million.
  • The largest annual shift saw Operating Income plummeted 56.66% in 2023 before it soared 1661.93% in 2025.
  • A 5-year view of Operating Income shows it stood at -$7.8 million in 2021, then fell by 7.83% to -$8.4 million in 2022, then fell by 24.77% to -$10.5 million in 2023, then soared by 223.59% to $12.9 million in 2024, then skyrocketed by 357.05% to $59.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Operating Income are $59.1 million (Q4 2025), $51.3 million (Q3 2025), and $19.5 million (Q2 2025).